Current knowledge of miRNAs as biomarkers in breast cancer
Breast cancer (BC) is the most common malignancy in women worldwide.
Breast cancer related mortality has dropped significantly since the widespread
adoption of mammographic screening. Approximately, 5% of the patients with BC
carry germline mutations that are responsible for their condition. Women carrying a
BRCA 1 or 2 mutation have a 57% and 49% lifetime risk of developing breast cancer,
respectively. For BRCA1/2 patients reluctant to a prophylactic surgery, the only
risk reducing strategy remains an increased imaging and clinical surveillance.